A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.

Trial Details

NCT ID
NCT06950034
Phase
PHASE1
Sponsor
Solu Therapeutics, Inc
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • STX-0712
Locations (sample)
  • Stanford, California, United States|37.42411,-122.16608
  • Tampa, Florida, United States|27.94752,-82.45843
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • Portland, Oregon, United States|45.52345,-122.67621

Key Eligibility Criteria

  • Refractory/resistant CMML, defined as: Diagnosis of CMML 1 or 2; and has not responded to at least 4 cycles of hypomethylating agents (HMAs)(for my…
  • Relapsed/refractory monocytic or monocytic predominant AML. Monocytic predominant AML is defined as ≥50% monocytes and/or monocytic precursors (pro…
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2.
  • Life expectancy of \>2 months and stable enough to complete two cycles of STX-0712, in the opinion of the Investigator.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →